Kornimate/medical-research-clean huggingface dataset:
a novel adaptive anastomotic technique for left-sided colonic resection

Conditions: Colon Neoplasm

Summary: the goal of this pilot clinical trial is provide preminary evidence of the effectiveness of the c-rex device, developed by carponovum ab, in preventing anastomotic leak and improving anastomosis healing after sigmoid or high rectal resection in patients with colon neoplasia. the primary aim of the study is to evaluate the rate of anastomotic leak in patients receiving the study device within 90 days from the surgical procedure.

despite technological advancements, the rate of anastomotic leak after left colon and high rectal resection remains high, around 20%. the device c-rex, developed by carponovum, may help the anastomosis construction and promote its healing. this may lead to reduced anastomotic leak rate and severity. this study aims to collect preliminary evidence on the effectiveness of c-rex to develop a future larger multicentric trial. this pilot study will collect preliminary data on the rate and severity of 90-day anastomotic leak in patients receiving the c-rex device.

Eligibility criteria:
inclusion criteria: * patients aged equal or more than 18 years old, both men and women. * patients with a proven diagnosis of sigmoid colon or high rectal tumors requiring anterior rectal resection as procedure of choice (colorectal cancer or benign polyps), as confirmed by radiological and histological exams. * patient indicated to minimally invasive or open sigmoid or high rectal resection. exclusion criteria: * patients with pre-existing health conditions requiring surgery, such as intestinal obstruction or perforation, local or systemic infections, peritonitis, or intestinal ischemia. patients with intraoperative evidence of any of these conditions will be withdrawn from the study. * patients with preoperative evidence of distal metastasis. patients with intraoperative evidence of distal metastasis or peritoneal carcinosis will be withdrawn from the study. * patients with documented intestinal or anal stenosis or other obstructions distal to the anastomosis. patients with intraoperative evidence of intestinal or anal stenosis will be withdrawn from the study. * patients who received radiation therapy to organs in abdomen or pelvis unrelated to current colorectal condition. * patients who are unable or received contraindication for the preoperative mechanical preparation. patients with a preoperative evidence or suspicion of incomplete colon cleansing will be withdrawn from the study. * patients indicated to defunctioning stoma. patients requiring diverting stoma as for intraoperative indication will be withdrawn from the study. * patients with an anastomosis in rectum below the peritoneal reflection and/or another procedure of choice than high anterior resection. * any condition that, in the opinion of the investigator, may interfere with the study conduction. in particular, any condition which can cause significant alteration of colonic wall thickness such as chronic and repeated infection which may impair the use of c-rex.

Keywords: colorectal neoplasms colorectal anastomosis anastomotic leak surgical device
covid-19 quick start - test and treat in africa

Conditions: COVID-19

Summary: duke university and the clinton health access initiative (chai), in partnership with the ministries of health (moh) of ghana, malawi, rwanda, zambia, and zimbabwe, aim to assess the implementation and impact of covid-19 test -and -treat (t\&t) demonstration programs

duke university and the clinton health access initiative (chai), in partnership with the ministries of health (moh) of ghana, malawi, rwanda, zambia, and zimbabwe, aim to assess the implementation and impact of covid-19 test -and -treat (t\&t) demonstration programs, titled "covid-19 quick start program". the mohs in collaboration with chai will implement sars-cov-2 antigen testing programs linked to patient triage and initiation of eligible patients on a complete course of oral antivirals for covid-19. the eligibility criteria and treatment regimens/duration may vary by country and over time depending on changes to guidelines. this mixed method study will leverage data from three independent data collection activities to guide implementation: 1. programmatic monitoring: a formative evaluation of the implementation of test and treat (t\&t) programs to identify implementation gaps and help implementers make evidence-based decisions and course-correct as needed. 2. collection of retrospective, patient-level data from treatment facility registers to understand impact of t\&t implementation on testing and treatment initiation rates, as well as costs of treatment initiation for cost modeling. 3. qualitative semi-structured interviews with key stakeholders including moh and public sector personnel, healthcare workers, and patients to understand the feasibility and acceptability of the program. data from this operational research study will help to ensure optimized delivery of t\&t programs in low- and middle-income countries as the availability of therapeutics for covid-19 scales up globally.

Eligibility criteria:
inclusion criteria: * 18 years and older * able to provide informed consent * patients who have received covid-19 testing and/or treatment at the facility * have a positive covid-19 test and were prescribed oral antiviral medication (and may or may not have initiated on treatment (only for subset of patients who will be followed to assess treatment completion and outcomes) exclusion criteria: none if other inclusion criteria are met
sequence towards remission in depression

Conditions: Depression

Summary: in this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. the investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. in this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. measures include, but are not restricted to, limbic emotional reactivity as assessed by fmri, emotional processing, emotional memory, autobiographical memory.


Eligibility criteria:
inclusion criteria: * major depressive disorder with current major depressive episode according to a scid-i/p interview * montgomery-åsberg depression rating score 15-30 * age 18-60 exclusion criteria: * borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder * primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3, 309.81, 308.3, 293.89 * significant current suicidal ideation, or history of a suicide attempt * lifetime substance dependence; last-year substance abuse; last month over 24/16 standard doses of alcohol/week; lifetime use of illicit substances \> x5; any illicit substance use in last month * depressive disorder due to medical condition or chemical substance * antidepressant medication use in last 4 months * severe, unstable somatic illness * use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)

Keywords: depression emotional processing fmri autobiographic memory moderator of treatment response mediator of treatment response
phase ii study of azd2281 in patients with known brca mutation status or recurrent high grade ovarian cancer or patients with known brca mutation status/ triple neg breast cancer

Conditions: Ovarian Carcinoma; Breast Cancer

Summary: this is a phase ii, open label, non randomized correlative study of azd2281 in patients with recurrent breast and ovarian cancer in both brca inherited mutation carriers and non-carriers to identify objective response rate and to assess for early markers of activity and to assess correlative markers that may provide helpful information for subsequent clinical trials. approximately 110 patients from 7 centers in canada will be enrolled into this study


Eligibility criteria:
inclusion criteria: * histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum * oestrogen, progesterone and her2 negative advanced adenocarcinoma of the breast * known brca positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma. * performance status of no more than 2. exclusion criteria: * any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry * major surgery with 4 weeks of entering the study and must have recovered from effects of any major surgery .

Keywords: breast cancer ovarian cancer brca triple negative poly(adp ribose) polymerases known brca or recurrent high grade serious/ undifferentiated tubo- ovarian carcinoma known brca or triple negative breast cancer
the application of music therapy in female amphetamine use disorder

Conditions: Amphetamine Addiction

Summary: the group music therapy will be used to treat female amphetamine-type stimulant (ats) addiction

amphetamine addicts are often accompanied by severe emotional problems and are difficult to control and regulate negative emotions by themselves.and the emotional problems are high risk factors of addicts relapse. music therapy as the intervention is in order to improve amphetamine addicts' emotional status and the ability of emotion regulation. self-rating depression scale(sds), self-rating anxiety scale(sas) will be used to investigate the emotion of participants. these methods will also be used to evaluate the efficacy of the intervention.

Eligibility criteria:
inclusion criteria: * in accordance with the diagnostic and statistical manual of mental disorders-5 (dsm-5) for methamphetamine (ma) use disorder * junior high school degree or above * normal vision and hearing * have emotional problem exclusion criteria: * other substance abuse or dependence in recent a years (except nicotine) * mental impairment, intelligence quotient (iq) \< 70 * mental disorders * physical disease

Keywords: music therapy depression emotion motivation
yoga for family caregivers of alzheimers disease patient

Conditions: Stress; Anxiety; Compassion

Summary: this study evaluates the effects of the practice of yoga in combination with compassion meditation on the quality of life, attention, vitality and self-compassion of family caregivers of patients with alzheimer's disease.

alzheimer's disease is a progressive brain disorder that involves the loss of reasoning, memory, language and the ability to live independently. thus, patients who suffer from this disease often require care from another person and must adapt to ensure their health, functional capacity and safety. caregivers have a poor quality of life due to the physical and psychological burden of caregiving. such physical, psychological, social and financial burden can increase the risk of death. within this scenario, techniques such as yoga and meditation have emerged as low-cost interventions that offer little or no risk to the practitioners. yoga seeks to develop health and attention through physical postures, breathing exercises and formal meditative practices.

Eligibility criteria:
inclusion criteria: * be a family caregiver of alzheimer disease patient * age over 18 years * completed at least the primary education level * at least at the phase of stress resistance according to lipp's inventory of stress symptoms for adults exclusion criteria: * patient with asthma or chronic obstructive pulmonary disease (copd) * alcohol use (more than 5 drinks per week) or use of drugs-of-abuse; * suffer from cushing's syndrome * under treatment with topical, nasal or any form of steroids within the last 30 days * practice yoga, meditation or similar techniques

Keywords: caregivers anxiety depression yoga meditation stress
clinical recruitment of patients with first-line targeted drug resistance or intolerance to hepatocellular cancer with pd-1 inhibitor (toripalimab,js001) detected on the ngs platform combined with anlotinib

Conditions: Hepatocellular Cancer

Summary: pd-1 inhibitors have become the standard treatment for advanced hepatocellular cancer, while targeted drugs such as sorafenib and lenvatinib are the first-line standard treatment for hepatocellular cancer. recent studies have shown that pd-1 inhibitors combined with targeted drugs can improve the efficacy of hepatocellular cancer.to clear the joint treatment in patients with advanced hepatocellular cancer (hcc) efficacy and evaluate its safety, we proposed to carry out the pd - 1 inhibitor (toripalimab, js001) joint anti-angiogenesis small molecules targeting drug anlotinib for clinical research,at the same time, based on joint solution of ngs platform testing to predict the curative effect, bring benefit for the long-term survival of patients with hepatocellular cancer (hcc).


Eligibility criteria:
inclusion criteria: 1. histological or cytological diagnosis of hepatocellular cancer; 2. at least one measurable lesion was assessed according to recist1.1 criteria. 3. age from 18 to 75,ecog physical strength score reaches 0-2; 4. after first-line targeted therapy, it was assessed as advanced or intolerant according to recist1.1 criteria. 5. child-pugh grade a or b for liver function; 6. bone marrow function was basically normal: neutrophils \> 1.5x 10\^9/l, platelets \> 75 x10\^9/l; 7. adequate renal reserve: creatinine \<130 mol/l; 8. centerless dysfunction, chest pain (medically uncontrollable), no myocardial infarction within 12 months prior to study initiation; 9. estimated survival ≥3 months; 10. signed the informed consent. exclusion criteria: 1. previous application of pd-1 inhibitor and anlotinib; 2. secondary malignant tumors or other tumors (except superficial skin cancer and localized low-grade malignant tumors) occurring within 3 years prior to the start of the study; 3. metastasis of the brain or meninges; 4. imaging findings indicated that the tumor was involved in important blood vessels or that the researchers had assessed that it might lead to fatal bleeding during follow-up; 5. bleeding events at any site ≥ctcae level 3 occurred 4 weeks before medication, and there were unhealed wounds, ulcers or fractures; 6. the time of occurrence of arteriovenous thrombosis, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within 6 months before enrollment; 7. untreated intestinal obstruction or subobstruction that cannot eat or affect systemic administration; 8. patients with active infection or other possible disorders receive inflammatory infections under planned management; 9. have a history of uncontrolled substance abuse or mental disorders; 10. in the judgment of the investigator, patients with concomitant diseases that may seriously endanger their own safety or may affect the completion of the study; 11. participated in other clinical trials; 12. pregnant and nursing women;

Keywords: antotinib toripalimab
mhealth facilitated intervention to improve hiv pre-exposure prophylaxis adherence

Conditions: Pre-Exposure Prophylaxis; Telemedicine; Medication Adherence

Summary: if taken every day, prep is an effective method for preventing hiv. however, many prescribed prep in the u.s. do not take it every day, as prescribed. the goal of this study is to develop and test an intervention, facilitated by a mobile app, meant to improve adherence to prep. to that end, 60 individuals prescribed prep who do not take their prep every day as prescribed will be recruited. participants will complete an initial research interview, receive a one-on-one prep adherence session with an adherence coach, and complete follow-up interviews at 1, 3, 6, and 12 months. in addition, some participants will be randomized to receive access to a mobile app and adherence coaching via the app for 12-months. the primary outcome is self-reported adherence to prep. this study will examine whether this intervention is effective at improving adherence to prep, is feasible to use, and found acceptable by those who use it.

hiv pre-exposure prophylaxis (prep), involves the use of antiretroviral (art) medications (truvada or descovy) by persons uninfected with hiv to prevent hiv acquisition. the efficacy of prep for preventing hiv acquisition is highly impacted by one's medication adherence. within the u.s., adherence to prep is suboptimal. commonly cited barriers to prep adherence include forgetfulness, low hiv risk perception, stigma, and cost. there is a need for interventions that improve adherence to prep, are readily disseminable, and that make efficient use of resources. to that end the current project will examine the feasibility, acceptability, and preliminary efficacy of an intervention tailored for prep adherence, facilitated by mhealth. individuals prescribed prep (n = 60) who report taking, on average, fewer than 6 doses per week in the past month will be recruited. participants will be randomly assigned to the intervention (carium) or control condition. data collection will consist of a baseline interview and follow-ups at 1, 3, 6, and 12 months. the primary outcome is prep adherence. prep adherence will be measured via self-report, pill counts, and use of a urine test developed by ursure. the urine test is for research use only and will only be used to detect the presence of prep in urine if participants self-report taking prep in the last 48 hours. it is expected that participants in the carium condition, relative to control, will report better adherence to prep.

Eligibility criteria:
inclusion criteria: * at least 18 years of age, * has a prescription for prep * received first prescription for prep at least one month ago * reports taking an average of fewer than 6 prep doses per week of over the past month * has phone that is compatible with the carium app. exclusion criteria: * cognitive impairment that would jeopardize informed consent and/or intervention comprehension * active psychosis * not fluent in english.

Keywords: prep adherence mhealth
fiber intake among children in relation to milk type, gastrointestinal symptoms and iron status: a cross-sectional study

Conditions: Healthy Children

Summary: fiber as part of the plants can be provided through eating grains, fruits and vegetables. as source of fiber, exclusively breastfed infants do not need additional dietary fiber because breast-milk provides oligosaccharides to maintain the bulk for normal gastrointestinal movements together with gut probiotics. however, after the period of six months of exclusive breastfeeding, then complementary foods are the initial sources of fiber of children aged 6-59 months diet, e.g. cereals, fruits and legumes should then be introduced. however, investigators should consider on the effect of plant foods as a non-haem iron food source that is less bioavailable for iron absorption. there are other dietary factors that inhibit iron bioavailability, i.e. phytates in grains and rice, vegetables protein, calcium and phosphorus in cow's milk and cheese. iron deficiency is remained common globally, especially for children age 6-24 month in which it can developing into a severe condition, i.e. iron deficiency anemia. iron deficiency as well as anemia is closely related to delay child growth and development, negatively associated with height-for-age, and anemia are at risk for poorer cognitive, motor, social-emotional, and neurophysiologic development in the short- and long-term outcome. the aim of this study is to see the association between fiber intake from different type of milk consumption sources and dietary habits to gastrointestinal health, anemia and growth status among children aged 6-36 months.

this study is an observational cross-sectional study to get fiber intake profile among children aged 6-36 months in relation to cow's and non-cow's milk consumption, gastrointestinal symptoms, hemoglobin value and nutritional status. the participants in this study are children aged 6-36 months who are recruited from selected puskesmas (health care center) in jakarta and bandung after provided with informed consent from children's parents. to get proportion of low fiber intake with a degree of reliability 95% and significance level of 5%, then 400 subjects is needed as a minimal sample size in this study. the children's parents will be interviewed about socio-demographic characteristics of the subjects, gastrointestinal symptoms during the past two weeks using vas (visual analogue scale) on frequency of bowel movements in a week, parents's education, family income, and child's food intake. the children's weight and height will be measured and blood sample will be taken.

Eligibility criteria:
inclusion criteria: * children aged 6-36 months who are recruited from selected puskesmas (health care center) in jakarta and bandung after provided with informed consent from their parents exclusion criteria: * children who are seriously ill and/or need special medication
safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of bi 187004 in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of bi 187004 following multiple dose administration over 14 days.


Eligibility criteria:
inclusion criteria: 1. type 2 diabetes mellitus 2. current treatment with no more than one anti-diabetic drug (except for insulin and glp-1 analogues) 3. males or post-menopausal or surgically sterilised females 4. age from 20 and to 70 years 5. hba1c less or equal to 8.5% 6. bmi 28-40 kg/m2 7. subjects must be able to understand an comply with study requirements exclusion criteria: 1. any finding in the medical examination (including bp, pr or ecg) deviating from normal that the investigator considers to be of not acceptable clinical relevance 2. repeated measurement of systolic blood pressure greater than 160 mm hg or diastolic blood pressure greater than 95 mm hg 3. myocardial infarction, stroke or transient ischemic attack within 6 months prior to informed consent 4. gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia or medically treated hypertension 5. surgery of the gastrointestinal tract that might affect absorption and elimination of the study drug 6. diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy 7. chronic or relevant acute infections (e.g. hiv, hepatitis)
transrectal photoacoustic imaging of the prostate

Conditions: Prostate Cancer

Summary: the purpose of this study is to image human prostate tissue using a new transrectal photoacoustic imaging probe and correlate this with ultrasound and mri imaging performed once the specimen has been surgically removed. we hope to see what we can visualize with our device as this has never been done before. eventually, we hope to use a similar device to image the prostate in men being seen by their doctor for prostate cancer.


Eligibility criteria:
inclusion criteria: * diagnosed with clinically-localized prostate cancer * participant desires prostatectomy * male * patient receiving treatment at palo alto veterans administration (va) hospital * age 18 to 80 years old * english-speaking exclusion criteria: * cannot tolerate a surgical prostatectomy due to medical comorbidities * cannot give informed consent

Keywords: prostate cancer transrectal imaging